Drug profile · INN
dabrafenib mesilate
TAFINLAR INITIAL APPROVAL
dabrafenib mesilate (TAFINLAR INITIAL APPROVAL) is a serine/threonine-protein kinase b-raf inhibitor.
PMDA: approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — dabrafenib mesilate
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.78
Quick answer
dabrafenib mesilate (TAFINLAR INITIAL APPROVAL) is a serine/threonine-protein kinase b-raf inhibitor.
Key facts
INN dabrafenib mesilate
Brand TAFINLAR INITIAL APPROVAL
Mechanism Serine/threonine-protein kinase B-raf inhibitor
Target Serine/threonine-protein kinase B-raf
Mechanism of action
Serine/threonine-protein kinase B-raf inhibitor
Primary target: Serine/threonine-protein kinase B-raf
Approval history
| Authority | Status | Date |
|---|---|---|
| PMDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is dabrafenib mesilate?
dabrafenib mesilate (TAFINLAR INITIAL APPROVAL) is a serine/threonine-protein kinase b-raf inhibitor.
What is the brand name for dabrafenib mesilate?
TAFINLAR INITIAL APPROVAL is a marketed brand name for dabrafenib mesilate. Check FDA Drugs@FDA for the current US label holder and prescribing information.